|
|
|
|
|
Received: 12 September 2017
|
|
|
|
|
|
| [1] |
薛 坤. 复方妥英麻黄茶碱片导致神经系统功能损害的临床分析[J]. 医学信息, 2015, (30): 363.
|
| [2] |
任夏洋. CYP2C19和CYP2C9基因多态性对苯妥英钠血药浓度的影响[D].北京:首都医科大学, 2011.
|
| [3] |
Shanmugarajah P D, Hoggard N, Aeschlimann D P, et al. Phenytoin-related ataxia in patients with epilepsy: clinical and radiological characteristics[J]. Seizure, 2018, 56: 26-30.
|
| [4] |
Delorenzo R J, Glaser G H. Effect of diphenylhydantoin on the endogenous phosphorylation of brain protein[J]. Brain Res, 1976, 105(2): 381-386.
|
| [5] |
Hergenroeder G W, Redell J B, Moore A N, et al. Biomarkers in the clinical diagnosis and management of traumatic brain injury[J]. Mol Diagn Ther, 2008, 12(6): 345-358.
|
| [6] |
Anseeuw K, Mowry J B, Burdmann E A, et al. Extracorporeal treatment in phenytoin poisoning: systematic review and recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup[J]. Am J Kidney Dise, 2016, 67(2): 187-197.
|
| [1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 713-715. |
|
|
|
2018, Vol. 29 
